Remsima 120 mg solution for injection in pre-filled pen

DRUG6 trials

Sponsors

AstraZeneca AB, Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif, Celltrion Inc., St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr, Amsterdam UMC Stichting

Conditions

Advanced Hepatobiliary CancerAxial SpondyloarthritisCrohn's diseaseCrohn´s diseaseRheumatoid arthritisUlcerative Colitis

Phase 2

A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

RecruitingCTIS2022-502317-29-00

AstraZeneca ABAdvanced Hepatobiliary Cancer

Start: 2023-07-12Target: 60Updated: 2025-12-11

Phase 3

A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis

Active, not recruitingCTIS2024-510945-32-00

Celltrion Inc.Rheumatoid arthritis

Start: 2024-12-17Target: 189Updated: 2026-01-26

Phase 4

Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL trial

Active, not recruitingCTIS2023-508242-18-00

Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube DigestifCrohn's disease

Start: 2021-12-21Target: 185Updated: 2025-09-17

A Prospective Multicenter Randomized Controlled, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn’s Disease ( Direct-CD)

CompletedCTIS2024-517171-20-00

Amsterdam UMC StichtingCrohn's disease

End: 2025-11-20Target: 158Updated: 2024-09-05

Direct comparison between NSAIDs and biosimilar TNFa blockers in patients with axial spondyloarthritis

RecruitingCTIS2024-513213-13-00

St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-RuhrAxial Spondyloarthritis

Start: 2025-03-13Target: 100Updated: 2025-09-06

Fecal microbiota transplantation in patients receiving infliximab and vedolizumab for ulcerative colitis: A randomized controlled trial

Not yet recruitingCTIS2024-520373-12-00

Varsinais-Suomen hyvinvointialueCrohn´s disease, Ulcerative Colitis

Target: 40Updated: 2025-01-21